Linker ID	LIN0GZQER
Linker Name	mp-dLAE-PABC
Antibody-Linker Relation	Cleavable

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	8%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	65%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	72%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	84%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	162 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.32 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	32%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	72%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	78%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	79%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	86%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	21 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	31 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	33%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	72%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	83%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	83%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	86%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	88%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	104 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.1 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.64 uM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	36%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	74%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	76%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	90%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	28 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	60 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	64 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	369 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	678 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	41%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	71%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	77%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	78%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	81%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	17 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	27 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 2000 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	46%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	75%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	76%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	78%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	81%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	25 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.37 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	48%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	77%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	84%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	88%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	10 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	56 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	215 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.62 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	50%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	70%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	75%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	80%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	24 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.41 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	69%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	73%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	83%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	85%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	95%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	2 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	52 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	856 nM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	74%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	81%	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	84%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 4 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	87%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 5 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	89%	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 6 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Maximum inhibition efficiency (MIE)	93%	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 7 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	4 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	COLO 853 cells		CVCL_2003
Experiment 8 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-28 cells		CVCL_0526
Experiment 9 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Cutaneous melanoma	SK-MEL-5 cells		CVCL_0527
Experiment 10 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	52 nM	Moderate CD228 expression (CD228++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	A2058 cells		CVCL_1059
Experiment 11 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	100 nM	Positive CD228 expression (CD228+++/++)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Melanoma	IGR-37 cells		CVCL_2075
Experiment 12 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1.14 uM	Low CD228 expression (CD228+)
Method Description	Tumor cells were incubated with CD228 antibody-drug conjugates comprising theindicated anti-CD228 antibody, a linker, and MMAE for 96-144 hours at 37 . Cell viability was measured using Cell Titer Glo according to manufacturer's instructions.
In Vitro Model	Amelanotic melanoma	A-375 cells		CVCL_0132

Ref 1	Anti-cd228 antibodies and antibody-drug conjugates; 2022-02-10.